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Psychotic symptoms frequently occur in Parkinson’s disease (PD), but their pathophysiology 
is poorly understood. According to the National Institute of Health RDoc programme, 
the pathophysiological basis of neuropsychiatric symptoms may be better understood in 
terms of dysfunction of underlying domains of neurocognition in a trans-diagnostic fash-
ion. Abnormal cortico-striatal reward processing has been proposed as a key domain 
contributing to the pathogenesis of psychotic symptoms in schizophrenia. This theory 
has received empirical support in the study of schizophrenia spectrum disorders and 
preclinical models of psychosis, but has not been tested in the psychosis associated 
with PD. We, therefore, investigated brain responses associated with reward expectation 
and prediction error signaling during reinforcement learning in PD-associated psychosis. 
An instrumental learning task with monetary gains and losses was conducted during an 
fMRI study in PD patients with (n = 12), or without (n = 17), a history of psychotic symp-
toms, along with a sample of healthy controls (n = 24). We conducted region of interest 
analyses in the ventral striatum (VS), ventromedial prefrontal and posterior cingulate 
cortices, and whole-brain analyses. There was reduced activation in PD patients with a 
history of psychosis, compared to those without, in the posterior cingulate cortex and 
the VS during reward anticipation (p < 0.05 small volume corrected). The results suggest 
that cortical and striatal abnormalities in reward processing, a putative pathophysiolog-
ical mechanism of psychosis in schizophrenia, may also contribute to the pathogenesis 
of psychotic symptoms in PD. The finding of posterior cingulate dysfunction is in keeping 
with prior results highlighting cortical dysfunction in the pathogenesis of PD psychosis.
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inTrODUcTiOn
Psychotic symptoms, such as hallucinations, paranoia, and delusions, are present in about 15–40% 
of Parkinson’s disease (PD) patients and may have a major impact on quality of life and likelihood 
of nursing home placement (1–5).
Several pathophysiological mechanisms have been proposed to explain how psychotic symptoms 
develop in PD. It has been suggested that visual hallucinations in PD develop as a consequence of 
cortical degeneration in posterior cortical areas (6, 7). An alternative to a single locus account of PD 
psychosis (PDP) is that the psychosis emerges through interactions between subcortical and cortical 
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pathological processes, or through the interaction of frontal and 
posterior cortical deficits, or through interaction between intrin-
sic disease-related factors and extrinsic drug factors (3, 4, 7–11).
There have been comparatively few attempts to integrate 
mechanistic explanations of psychotic symptoms in PD with 
current models of their pathophysiology in primary psychiatric 
illness. In spite of clear potential differences in the pathogenesis 
of psychiatric symptoms in PD compared to primary psychiatric 
illness (2, 12), there may be common pathways for the manifesta-
tion of certain neuropsychiatric symptoms across traditional 
diagnostic categories (6, 13). A longstanding candidate contribu-
tor cause of psychosis in PD is a dopaminergic system perturbed 
by a combination of intrinsic pathology and extrinsic medication, 
as dopaminergic drugs are strong risk factors for the manifesta-
tion of psychotic symptoms in PD: odds ratios for hallucinations 
are up to fivefold for dopamine agonist treatment compared to 
placebo in a meta-analysis (14). Furthermore, withdrawal of dopa-
minergic medication or dose reduction frequently brings relief 
from psychotic symptoms (11). There is already a large literature 
implicating dopamine and serotonin neurotransmission in the 
pathogenesis and treatment of schizophrenia spectrum psychosis 
and preliminary evidence linking fronto-striatal dopaminergic 
function to schizotypal traits in the general population (15–18). 
The recently identified role for serotonin in the pathology and 
treatment of PDP (19, 20) further weight for consideration of at 
least some potential commonalities in the pathophysiology of 
psychosis in schizophrenia spectrum conditions and PDP.
Abnormal dopaminergic (21, 22) and cortico-striatal (23, 24) 
function manifesting in altered processing of rewards and reward 
prediction, have been proposed as key factors contributing to 
the pathogenesis of psychotic symptoms. These accounts have 
received empirical support in the study of psychosis in schizo-
phrenia spectrum disorders and preclinical models of psychosis 
(23, 25–31), but have not been tested in PDP. However, there is 
already evidence for this from a number of studies of both corti-
cal and subcortical dysfunction during reward processing in PD 
(32–34). These factors merit the further investigation of cortico-
striatal reward processing as a putative neurocognitive process 
potentially contributing to the pathogenesis of PDP.
In this study, we have focused on the neural basis of prediction 
of a reward and the representation of reward prediction error: 
processes with previous theoretical and empirical support for 
their involvement in the pathophysiology of psychotic symptoms 
in schizophrenia. A recent meta-analysis found evidence of 
ventral striatal dysfunction associated with both of these neuro-
cognitive processes in schizophrenia spectrum psychosis (31), so 
we elected to study the ventral striatum (VS) as a region of interest 
(ROI) in our cohorts of PD patients. We aimed to complement 
this subcortical ROI with analysis within two cortical ROIs, the 
ventromedial prefrontal cortex and posterior cingulate cortex 
(PCC), where we previously identified a link between abnormal 
activation during reward processing and psychotic symptom 
expression (23).
Our hypothesis was that patients with PD psychosis should 
present reductions in PCC, ventromedial prefrontal cortex, and 
ventral striatal activations associated with reward anticipation 
and prediction error relative to PD patients without psychosis.
MaTerials anD MeThODs
Participants
The final sample was composed of 53 participants: 17 patients 
with a diagnosis of PD without any psychotic symptoms (PD); 12 
patients with a diagnosis of PD and a history of current or previ-
ous psychotic symptoms (lifetime CAARMS scoring equal to or 
greater than 3 in global and frequency scales) (PDP); 24 healthy 
volunteers, with no history of neurological, psychiatric, or medical 
disorders (controls). The initial sample was composed of 66 par-
ticipants. Ten participants (8 PD, 1 PDP, 1 control) were excluded 
due to technical programming problems, which occurred during 
the task (responses not recorded, N = 9), or to the fMRI scanning 
(wrong scanning protocol, N =  1). Three additional subjects (2 
PD, 1 control) were excluded because they did not complete the 
task. Patients were recruited via the PD research clinic at the John 
van Geest Centre for Brain Repair (VGB); all fulfilled the Queen 
Square Brain Bank Criteria for idiopathic PD (35) and remained 
on their usual medications during testing. Each patient’s dopa-
minergic drug regime was converted to an equivalent l-DOPA 
dose (36). Patients with dementia were excluded [operationalized 
as a Mini-Mental State Examination (37) score less than 24]. 
Descriptive statistics of the sample are reported in Table  1. All 
subjects had normal or corrected-to-normal visual acuity and 
were without any contraindications for MRI scanning.
Operational Definition of PDP
We defined the presence of PDP using a sensitive instrument 
measuring mild psychotic symptoms from the field of early detec-
tion of schizophrenia spectrum psychosis: the Comprehensive 
Assessment of At Risk Mental States (38, 39). This scale allows 
for sensitive measurement of a spectrum of psychotic experiences 
and includes measures on both the frequency and severity of 
symptoms. For example, the perceptual aberration scale scores 
of severity can range from 0 (no abnormality), 1 (questionable 
perceptual changes), 2 (heightened or dulled perceptions, illu-
sions), through to 6 (a true hallucination that the patient believes 
true at the time and after the experience). The instrument takes 
these measures and operationalizes a categorical definition of 
attenuated psychosis (e.g., on the perceptual abnormalities scale, 
a 3 would be required for severity and frequency, indicating at 
least an intense illusion, “subject unsure of the nature of the 
experience,” with frequency of at least once per month if lasting 
over an hour per occasion or over 3 times per week if shorter). 
We reasoned that this threshold has been meaningful in clinical 
psychiatric practice (40) and could represent not only a sensitive 
but also a clinically meaningful way of classifying PD patients as 
having experienced psychosis or not. As we were interested in the 
propensity to psychosis in PD, we included patients in the PDP 
group with current and past (post PD onset) psychosis, even if 
the psychotic symptoms had resolved or improved by the time 
of the study.
rating scales
The Beck Depression Inventory (41) was used to assess depressive 
symptoms during the last 2 weeks. The Apathy Evaluation Scale 
Table 1 | Descriptive statistics.
characteristics control PD PD psychosis Test p-Value
Demographics
Participants, n 24 17 12
Age, mean (SD), years 61.91 (5.83) 63.29 (9.94) 60.83 (6.6) F(2,50) = 0.39 0.68
Gender, M/F (% male) 10/14 (43) 10/7 (56) 6/6 (50) χ2 (2) = 1.17 0.55
Handedness R/L (% right) 22/1 (96) 15/3 (83) 11/1 (92) χ2 (2) = 0.15 0.92
White-British, n (%) 22 (91.66) 17 (100) 12 (100) χ2 (2) = 2.51 0.28
Educational qualifications
No qualifications (%) 3 (12.5) 1 (5.88) 0 (0) χ2 (2) = 1.89 0.38
16/18 years old qualif. (%) (GSCSEs, A-level or eq.) 10 (41.66) 6 (35.29) 6 (50) χ2 (2) = 0.62 0.73
Degrees, advanced vocational qualif. (%) 11 (48.83) 10 (58.82) 6 (50) χ2 (2) = 0.67 0.71
cognitive function
MMSE—total, mean (SD) 30.30 (3.08) 28.94 (1.59) 28.41 (1.37) F(2,49) = 3.07 0.07
Estimated IQ, mean (SD) 102.04 (11.92) 89.64 (14.59) 86.54 (13.45) F(2,49) = 7.1 0.002
Controls vs all PD p < 0.01; PD vs PDP p = 0.1
PD
Hoehn and Yahr stage, % 1/2/3/4/5 – 59/35/0/0/6 60/10/30/0/0 χ2 (1) = 0.5 0.72
Duration, years mean (SD) – 10.94 (10.38) 16.42 (28.77) t(27) = −0.81 0.43
Medications
Levodopa equivalent dosage, mean (SD) – 614.81 (503.42) 714.03 (531.42) t(22) = 0.5 0.61
Levodopa therapy, n (% yes) 13 (76.47) 9 (75) χ2 (1) = 0.00 0.9
DA agonist, n (% yes) 8 (47.05) 10 (83.33) χ2 (1) = 2.54 0.11
Antidepressants, n (% yes) – 7 (41.17) 1 (8.33) χ2 (1) = 2.33 0.12
Anxiolytics, n (% yes) – 3 (17.64) 3 (25) χ2 (1) = 0.009 0.92
Psychopathology
BDI total, mean (SD) 3.08 (3.69) 8.88 (4.94) 12.66 (7.83) F(2,50) = 14.73 <0.001
Controls vs all PD p < 0.003; PD vs PDP p = 0.1
Apathy Evaluation Scale total, mean (SD) – 32.1 (10.7) 33 (8.6) t(22) = 0.23 0.82
caarMs score equal or over 3, global rating scales
Unusual thought content – – 0 – –
Non-bizarre ideas, n (%) – – 3 (25) – –
Perceptual abnorm., n (%) – – 9 (75) – –
Disorganized speech, n (%) – – 2 (16.66) – –
Characteristics of the whole sample separated into the three groups: controls, Parkinson’s disease (PD) without, and PD with psychosis. The inclusion criterion for the psychosis 
group is Lifetime Comprehensive Assessment of At Risk Mental States scale (CAARMS, which measures psychotic symptoms) scoring equal or over 3 in global and frequency 
scales. BDI, Beck Depression Inventory. MMSE, Mini-Mental State Examination. IQ was estimated using the Culture Fair test. Only one patient in the study (PDP group) was taking 
antipsychotic medication (100 mg quetiapine twice daily).
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(self-complete) assessed apathy (42). IQ was estimated using the 
Culture Fair test (43). The Hoehn and Yahr scale (44) was used to 
assess the stage of PD in patients.
fMri cognitive Task
During the fMRI scan, subjects performed a computerized 
instrumental learning task based on that used in previous studies 
(23, 45–48).
During the task, participants were presented with two fractal 
images and required to choose one of them, with a button press, 
in order to maximize their payoffs. Each choice was followed by 
a visual feedback indicating the associated outcome. There were 
three possible trials: during Reward Trials, one choice was associ-
ated with a £1 win in 80% of trials and with neutral feedback in 
20% of trials [High-Likelihood (HL)], whereas the other choice 
was associated with a neutral outcome in 80% of trials and with 
a £1 win in 20% of trials [Low-Likelihood (LL)]; during Bivalent 
Trials, each choice was associated with a 50% chance of either 
losing or winning £1; during Neutral Trials, each choice was 
associated with a 80/20% chance of receiving two kinds of neutral 
feedback (Figure 1). Each trial type was repeated 30 times in a 
pseudo-random sequence, for a total of 90 trials. The order and 
position of the pictures presented were counterbalanced across 
trials of the same kind. To win money, the participants had to 
learn, by trial and error, to select the stimulus that was more 
likely to produce a reward. All participants were informed that 
the total amount won during the task would be paid to them at 
the end of the experimental session. All participants underwent 
a training session before entering the scan in which they received 
an explanation of the task, and practiced it for 5 min.
fMri Data acquisition and analysis
A Siemens Magnetom Trio Tim operating at 3  T was used to 
collect imaging data. Gradient-echo, echo planar T2*-weighted 
images, depicting bold contrast were acquired from 35 non-
contiguous oblique axial planes to minimize signal drop-out in 
ventral regions. TR was 1,620 ms; echo time was 30 ms; flip angle 
was 65°; in-plane resolution was 3.0 × 3.0, matrix size was 64 × 64; 
field of view was 192 mm × 192 mm, bandwidth 2,442 Hz/Px. A 
total of 550 volumes per subject were acquired (27 slices each 
FigUre 1 | Visual representation of the instrumental conditioning task. Participants were presented with two fractal images and were required to choose one 
of them in order to maximize their payoffs. Each choice was followed by a visual feedback indicating the associated outcome. During Reward Trials, one choice was 
associated with an 80% chance to win £1 [High-Likelihood (HL)] and the other choice was associated with a 20% chance to win £1 [Low-Likelihood (LL)]. During 
Bivalent Trials, each choice was associated with a 50% chance of either losing or winning £1. During Neutral Trials, each choice was associated with an 80/20% 
chance of receiving two kinds of neutral feedbacks.
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of 2 mm thickness, interslice gap 1 mm). The first five volumes 
were discarded to allow for T1 equilibration effects. Slice-timing 
correction was applied.
The data were analyzed in SPM 12 software (Wellcome 
Department of Cognitive Neurology, London, UK). Images 
were realigned, spatially normalized to a standard template, and 
spatially smoothed with a Gaussian kernel (8 mm at full-width 
half-maximum). A high-pass filter was applied (128 Hz).
A within subject analysis (often referred to as “first-level” 
analysis) was undertaken, regressors (explanatory variables) used 
in the general linear model were as follows: bivalent cue pres-
entation; neutral cue presentation; reward cue presentation; loss 
feedback during Bivalent Trials; win feedback during Bivalent 
Trials; neutral feedback 1 during Neutral Trials; neutral feedback 
2 during Neutral Trials; neutral feedback during Reward Trials; 
and win feedback during Reward Trials. All regressors were mod-
eled as 0 second events and convolved with the SPM canonical 
hemodynamic response function. Motion parameters were used 
as additional regressors to control for movement.
Contrasts of interest were computed at the individual subject 
level and then taken to a group level for statistical analysis. 
There were two main contrasts of interest: reward anticipation 
and prediction error. To measure reward anticipation, a contrast 
between the presentation of the reward cue minus the neutral cue 
was performed. To examine prediction error, a contrast between 
the presentation of win feedbacks during bivalent trials (where a 
reward is unexpected) minus a win on Reward Trials (where a win 
is expected) was performed.
The main contrast of interest at the group level was PDP in 
comparison to PD without psychosis, as this comparison con-
trols for many of the potential confounds that would be needed 
in any comparison of PDP with controls. We focused on a priori-
defined ROIs comprising medial orbitofrontal cortex, PCC, and 
bilateral VS (see Figure S1 in Supplementary Material). A single 
mask from these regions was created using spheres centered on 
the following MNI coordinates taken from the meta-analysis of 
reward anticipation by Liu et al. (49): 0, −30, 32 (posterior cingu-
late, 12 mm diameter); 0, 34, −8 (ventromedial prefrontal cortex, 
8 mm diameter); and bilateral VS (12, 10, −4, 8 mm diameter, 
and −12, 10, −4, 8  mm diameter). Results were considered 
significant where peak voxel activation survived a family-wise 
error small volume correction across the voxels of this mask at 
p < 0.05. For display of the clusters that passed this small volume 
correction and calculation of their cluster size, the uncorrected 
threshold was p = 0.005.
Movement
To ensure that the three groups did not differ in the amount of 
movement during the fMRI scanning session, the averaged time 
series of translations and rotations along the three axes (x, y, z), as 
estimated during the realignment phase of pre-processing, were 
compared across groups.
FigUre 2 | behavioral performance. (a) The total number of responses during the three trial types (Reward/Neutral/Bivalent) for the three groups (controls/ 
PD/PDP). (b) The reward learning index (HL–LL) for the three groups (controls/PD/Parkinson’s disease with psychosis). (c) Mean reaction times during the three trial 
types (Reward/Neutral/Bivalent) for the three groups (controls/PD/Parkinson’s disease with psychosis). HL, high-likelihood; LL, low-likelihood; 1, choice one; 2, 
choice two; PD, Parkinson’s disease. Bars indicate SE (***p < 0.0001; **p < 0.001; *p < 0.05).
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Two separate mixed-effects models were used, with Group 
(controls/PD/PDP) as the independent variable and translations 
(millimeter) or rotations (degrees) as the dependent variable.
No group differences were found either in the amount of 
translations (p = 0.35; part. η2 = 0.04) or rotations (p = 0.32; part. 
η2 = 0.04).
behavioral analysis
To analyze participants’ performance during the task, three 
separate 3 ×  2 mixed-effects models were performed for each 
trial condition (Reward/Neutral/Bivalent), using the total num-
ber of responses as the dependent variable (Figure 2A). Group 
(controls/PD/PDP) and Choice (HL/LL or 1/2) were used as the 
independent variables.
Demographic and clinical analysis
Analyses of the demographic and clinical characteristics from 
the whole sample are reported in Table 1. χ2 was used to com-
pare frequencies. For comparing means between groups, t-tests 
(comparison between PD/PDP) or ANOVAs (comparison 
between controls/PD/PDP) were used as appropriate. Significant 
differences were further investigated via Bonferroni-corrected 
post hoc analysis.
resUlTs
behavioral results
Results from Reward Trials showed a significant main effect of 
Choice [F(1,50) = 83.22; two-tailed p < 0.001; part. η2 = 0.62], 
evidencing a higher number of HL over LL choices and a Group 
X Choice interaction [F(2,50) = 4,42; two-tailed p = 0.02; part. 
η2 =  0.15]. Bonferroni-corrected post  hoc tests revealed a sig-
nificant difference only between controls and PDP for both HL 
(p <  0.01) and LL (p <  0.01) choices. On average, HL choices 
were performed more by controls (mean =  25.62, SD =  5.21) 
than PDP (mean = 19.25, SD = 8.31); whereas LL choices were 
performed less by controls (mean = 4.12, SD = 5.31) than PDP 
(mean = 10.58, SD = 8.36).
Results from Neutral and Bivalent Trials showed no statisti-
cally significant effect (p’s > 0.1).
A further 3 ×  3 mixed-effects model was performed using 
the reaction times as the dependent variable (Figure 2C). Group 
FigUre 3 | reward anticipation. Statistical parametric maps of the reward anticipation calculated on the contrast of reward minus neutral cues onset. Analyses 
are restricted to the regions of interest and overlaid on a standard space structural image. Significant effects, thresholded at p = 0.005 and family-wise error 
corrected at p = 0.05, are shown in yellow. The left hemisphere is displayed on the left. MNI coordinates are reported. Parkinson’s disease patients with psychosis, 
as compared with Parkinson’s disease patients, showed a significantly reduced activation within the posterior cingulate cortex and the right ventral striatum (VS) and 
a marginally significant reduced activation in the left VS.
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(controls/PD/PDP) and Trial type (Reward/Neutral/Bivalent) 
were used as the independent variables. Results showed a signifi-
cant main effect of Trial type [F(1,87) = 5.09; two-tailed p = 0.007; 
part. η2 =  0.03]. Bonferroni-corrected post  hoc tests revealed a 
significant difference only between Reward and Neutral Trials 
(p = 0.006). All other effects were not significant (p’s > 0.1).
Overall, these results indicate that participants, irrespective of 
the group, showed contingency learning during Reward Trials, 
expressing both as a preference for the HL choice (i.e., more 
frequently associated with a reward—80%) over the LL choice 
(i.e., less frequently associated with a reward—20%) and at faster 
reaction times when choosing during such trials, as compared with 
Bivalent and Neutral Trials—a well-replicated finding that has 
been referred to as “reinforcement-related speeding” (29, 45, 50). 
Nevertheless, controls presented a significantly higher ability to 
distinguish between choices with a higher and lower chance of 
rewards, as compared with PD patients with psychosis. Such a 
difference was subsequently directly tested by creating an index of 
the ability to learn from rewards (reward learning), obtained by 
subtracting for each subject the number of LL responses from the 
number of HL responses (Figure 2B). A mixed-effects model was 
performed using this reward learning index as the dependent vari-
able and Group (controls/PD/PDP) as the independent variable. 
Results showed a significant main effect of Group [F(2,50) = 4.37; 
two-tailed p =  0.02; part. η2 =  0.15]. This further analysis con-
firmed what had been observed with the previous analysis: control 
participants were better able to differentiate between choices with 
higher and lower chance of reward and to use this information to 
adapt their behavior. In this regard, it is important to note that PD 
patients with psychosis still showed a significant difference between 
HL and LL choices (HL > LL), so they did learn the contingencies 
during Reward Trials. Critically, no significant difference between 
PD patients with and without psychosis was found.
Neither choice preferences nor differences in reaction times 
were evidenced in Neutral and Bivalent Trials.
We also examined the number of actual rewards received during 
Reward Trials. A mixed-effects model was performed using the 
number of rewards received as the dependent variable and Group 
(controls/PD/PDP) as the independent variable. Results showed a 
significant main effect of Group [F(2,50) = 5.11; two-tailed p = 0.01; 
part. η2 = 0.17]. Bonferroni-corrected post hoc tests revealed a sig-
nificant difference only between controls and PDP (p < 0.02). On 
average, more rewards were received by controls (mean = 21.16, 
SD = 0.22) relative to PDP (mean = 17.25, SD = 4.39). Critically, 
no significant difference between PDP (mean = 17.25, SD = 4.39) 
and PD (mean = 18.17, SD = 4.39) was found (p > 0.9).
imaging results
Reward Anticipation
PD psychosis patients, as compared with PD patients, reported 
a significantly reduced activation in two clusters (Figure 3): one 
located within the PCC sphere [peak MNI coordinates x, y, z = 2, 
−20, 38; peak z = 3.65; peak p = 0.031 (small volume corrected); 
voxels = 59] and one located in the right VS [peak MNI coordinates 
x, y, z = 16, 16, −2; peak z = 3.60; peak p = 0.037 (small volume cor-
rected); voxels = 21]. A third cluster located in the left VS showed 
marginally significant reduced activation in PDP as compared to 
PD patients [peak MNI coordinates x, y, z = −16, 16, −2; peak 
z = 3.03; peak p = 0.077 (small volume corrected); voxels = 44].
Parameter estimates of the two significantly different clusters 
(PCC and right VS) were extracted for the three groups (controls, 
PD, PDP) and statistically compared (Figure 4).
FigUre 4 | Mean parameter estimates in the significant clusters. 
Mean parameter estimates of the reward anticipation contrast, extracted for 
the three groups (controls, PD, PDP), from the significantly different clusters 
found within the posterior cingulate cortex and right ventral striatum regions 
of interest. PD, Parkinson’s disease patients; PDP, Parkinson’s disease 
patients with psychosis. Bars represent SE.
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Two separate mixed-effects models, one for the PCC and one 
for the right VS, were performed using the extracted parameter 
estimates as the dependent variable. Group (controls/PD/PDP) 
was used as the independent variable. As the clusters are defined 
by differences between the PD and PDP groups, it is to be 
expected that these groups will show differences, but extraction of 
the cluster scores allows visualization of results and comparison 
against the healthy control group without PD.
Results in the PCC cluster showed a significant main effect 
of Group [F(2,50) = 4.89; two-tailed p = 0.01; part. η2 = 0.16]. 
Bonferroni-corrected post hoc tests revealed a significant differ-
ence between PD and PDP groups (p = 0.009). All other effects 
were not significant (p’s > 0.2).
Results on the right VS cluster showed a significant main effect 
of Group [F(2,50) = 5.54; two-tailed p = 0.007; part. η2 = 0.18]. 
Bonferroni-corrected post hoc tests revealed a significant differ-
ence between PD and PDP (p = 0.005) and a marginally signifi-
cant difference between controls and PDP (p = 0.058). Controls 
and PD were not significantly different (p = 0.73).
There were no differences that survived correction for multiple 
comparison between PDP and PD groups on the whole-brain 
analysis.
Although the PD and PDP groups did not significantly dif-
fer on depressive symptoms, nevertheless, the PDP group had 
non-significantly more depressive symptoms than the PD group. 
We, therefore, compared the extracted parameter estimates 
between PDP and PD, controlling for depressive symptoms using 
ANCOVA: the difference between PDP and PD remained in the 
PCC cluster [F(2,26) =  10.35, p =  0.003] and in the right VS 
[F(2,26) = 12.92, p = 0.001].
Prediction Error
There were no differences that survived correction for multiple 
comparisons between PDP and PD groups on ROI or whole-
brain analysis.
DiscUssiOn
In this study, we found abnormal brain activation in PDP associ-
ated with reward anticipation in the VS and PCC. The finding 
of psychosis-related abnormal striatal activity is novel for PD 
but in line with a significant body of literature in schizophrenia 
spectrum psychosis showing—across a wide range of procedures 
and manipulations—dysfunctional striatal processing of rewards 
(29, 51–56). Indeed, Radua et al. (31) recently confirmed on meta-
analysis the presence of ventral striatal dysfunction associated 
with reward anticipation in schizophrenia spectrum psychosis.
We found a significant deficit in reward anticipation activation 
in the right VS in the PDP group, but only a marginally significant 
deficit in the left VS. This differential sensitivity might reflect 
important biological processes or could simply be due to chance. A 
recent neurofunctional meta-analysis by Radua et al. (31) directly 
investigated a possible VS lateralization of reward processing 
in psychosis. The authors analyzed 23 studies (917 patients) for 
reward anticipation, 9 studies (358 patients) for reward feedback, 
and 8 studies (314 patients) for reward prediction error, reporting 
no differences between left and right VS in any of the reward 
processes considered. Based on these results, we feel it would 
be premature to draw conclusions from slightly stronger group 
differences for the right VS found in the present study.
The functional neuroanatomical basis of psychotic symptoms 
in PD has received little study using fMRI. The present study 
is the first cognitive fMRI study, to our knowledge, to compare 
PD patients with and without a history of psychotic symptoms 
considered broadly as we have done here (although it is prob-
able that some of the previous studies of hallucinations included 
patients with delusional ideation by chance). Previous studies 
have focused on comparing brain activation between PD patients 
with and without hallucinations, but only a handful have been 
conducted (57–61). Some studies did not make corrections for 
multiple comparisons, and one had a sample size of only three 
patients with hallucinations. Meppelink et  al. (59) examined 
visual processing in PD patients with and without hallucinations 
and found robust evidence for visual processing deficits in the 
patients with hallucinations in the superior frontal, lingual, and 
fusiform gyri. There were additional areas of group difference that 
did not survive correction for multiple comparisons.
A number of related theories have posited that abnormal 
brain mechanisms of learning and predicting the environment 
could contribute to the pathogenesis of psychosis (21, 26, 28, 62). 
The striatum is key in learning and updating ones beliefs in the 
light of experience (63); hence striatal dysfunction is a plausible 
candidate process that could underpin the formation of abnor-
mal beliefs (64). Contemporary neuroscience accounts of brain 
predictive processing emphasize the importance of prediction in 
determining perceptual experience, potentially explaining how 
brain predictive dysfunction could lead, not just to delusions, but 
also hallucinations (65). We previously showed that the degree of 
disruption to the representation of reward expected value in the 
PCC secondary to methamphetamine administration predicted 
the severity of psychotic symptoms induced by the drug (23); that 
previous study is consistent with the current results implicating 
posterior cingulate reward anticipation dysfunction in the patho-
physiology of psychotic symptoms.
Ramírez-Ruiz et  al. (60) examined activations elicited by 
a visual attention (face recognition) task. They found, using 
a cluster-correction threshold, reduced frontal activation 
in the superior and inferior frontal cortex in hallucinating 
8Garofalo et al. Reward Processing in PDP
Frontiers in Neurology | www.frontiersin.org April 2017 | Volume 8 | Article 156
patients compared to controls. Ramirez-Ruiz argued that their 
findings of frontal deficits in association with hallucination 
might indicate, in part, a particular difficulty in patients prone 
to visual hallucinations in differentiating between relevant 
and irrelevant visual information. A failure to differentiate 
between motivationally salient and irrelevant information has 
been argued to be a key mechanism in the pathophysiology 
of psychotic symptoms in schizophrenia (62). Our findings of 
reduced ventral striatal and PCC activation in the comparison 
of rewarding and neutral cues are interpretable as impairment in 
differential anticipation in relation to motivational salient and 
irrelevant information. Yao and colleagues’ (66) examination 
of resting-state fMRI differences between 12 PD patients with, 
and 12 without, visual hallucinations found resting-state differ-
ences in posterior cingulate connectivity between the groups, 
with no evidence of cortical thickness differences. Although we 
failed to find evidence of frontal reward prediction dysfunction 
in PDP or of prediction error-associated dysfunction in any 
of ROIs, this absence of evidence does not necessarily exclude 
these processes and regions being implicated in the pathogen-
esis of PDP.
Analysis of the behavioral performance in our study indicated 
that participants acquired a preference for the highly rewarded 
choice during Reward Trials (HL > LL), thus showing learning 
of the task contingencies. PD patients with psychosis displayed 
a significantly lower preference for the HL choice relative to 
controls. Nevertheless, in the PDP group, there was a significant 
preference for HL over LL choices, thus demonstrating learning. 
Critically, there were no differences between patients with and 
without psychosis, indicating that the imaging results were not 
confounded by learning deficits in PDP.
Although we cannot draw direct inferences about the neuro-
chemical basis of our findings, it is possible that monoaminergic 
function may contribute to our findings. There is evidence that 
dopamine abnormalities in the striatum, and possibly also sero-
toninergic abnormalities, contribute to psychotic symptoms in 
schizophrenia (15, 17), and there are separate lines of evidence 
suggesting that dopaminergic and serotonergic factors may 
contribute to psychosis in PD (11, 19, 20). Previous studies have 
indicated that serotoninergic manipulations modulate fMRI acti-
vation and connectivity in the PCC (67, 68). Serotonin neurons 
have been shown to be important in representing reward cues 
and outcomes (69), and serotonin receptors, including 5HT2a, 
are widely expressed in the cortex, including in the posterior 
cingulate (70, 71). 5HT2a receptors have also been associated 
with more general cognitive flexibility (72–74), which could also 
be relevant for the generation of psychotic symptoms; one recent 
research study found evidence that that a failure to flexibly adapt 
learning to the degree of volatility in the environment could 
contribute to the pathogenesis of psychosis (75). Subcortical 
dopaminergic neurotransmission plays a key role in reward 
processing and motivation (76, 77), and there is also evidence for 
monoaminergic modulation of reward predicting activity even in 
posterior cortical regions (78).
Our study has a number of strength and limitations. A novel 
aspect of the study is the attempt to reconcile investigative meth-
ods (interview scales, fMRI paradigm) examining the physiology 
of psychosis in PD and schizophrenia spectrum conditions. The 
small number of patients with PDP is common in this research 
field but remains a limitation, and definitive conclusions will 
require a much larger sample size. Another limitation is that 
we made no attempt to characterize the neuropsychological 
performance of our participants. As the PD and PDP groups 
performed the fMRI task at a similar level, our results are unlikely 
to be driven by neuropsychological differences. Nevertheless, 
psychotic symptoms in PD might be associated with a specific 
neuropsychological profile, and characterizing this is an impor-
tant goal of future research. A strength of our study is that the 
PD and PDP groups were well matched in terms of age and 
current medication: the daily l-DOPA equivalent dose did not 
differ across the PD groups. Levels of apathy and depression were 
comparable in the groups. However, a limitation of our study is 
that we did not record the timings of medication administration 
on the research day, and so we cannot eliminate the possibility 
that medication influence at the time of the scan might differ 
across the PD groups. There was no significant difference in 
terms of disease duration, although we note that our PDP group 
had a longer duration of illness than the PD group, in accordance 
with prior literature showing an association between psychotic 
symptoms and duration of illness (79–81).
Our findings suggesting a role for striatal and cingulate 
dysfunction in the pathogenesis of psychosis in PD should 
be taken in the context of an existing literature investigating 
PDP, mainly drawn from research modalities other than fMRI. 
This literature points to cortical abnormalities in PDP, such as 
reduced gray matter volume in the hippocampus and in frontal, 
parietal, and occipital cortices (6), and to the presence of Lewy 
bodies in frontal, cingulate, temporal, and occipital cortices on 
postmortem examination (9). Psychotic symptoms in PD are 
often comorbid with dementia and, in some cases, may presage 
incipient dementia (82). In the related disorder of dementia with 
Lewy bodies, posterior cortical–thalamic connectivity is related 
to hallucination severity (83). The dual syndrome hypothesis 
of cognitive impairments in PD (84) distinguishes between a 
non-dementia profile of fronto-striatal deficits (manifest in tests 
of executive function), and a profile of posterior cortical dysfunc-
tion with rapidly progressing cognitive decline to dementia. It 
is possible the psychotic symptoms in PD may emerge through 
either of these pathological processes or through an interaction 
of the two. In patients without global cognitive impairment, 
psychotic symptoms are often comorbid with other non-motor 
deficits, such as depression and sleep–wakefulness disturbance 
(3). A full account of psychosis in PD will need to take into 
account all of these complex factors in explaining why psychotic 
symptoms are commonly but not universally manifest in PD (12), 
which pathophysiological mechanisms are unique to PDP, and 
which are shared with mechanisms of psychotic experiences in 
schizophrenia or the general population (85). Our study adds to 
prior evidence of cortical dysfunction in PDP and suggests that 
there may be factors in common in the pathogenesis of schizo-
phrenia spectrum psychosis and PD psychosis. It is possible that 
these abnormalities may contribute to the understanding on how 
monoaminergic function contributes to psychotic symptoms 
in PD; future pharmacological fMRI studies could specifically 
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investigate this further by comparing, for example, the effects of 
5-HT 2a inverse agonists on reward activation in PDP.
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